Security record · archived quarter
JANX
Janux Therapeutics, Inc. · Healthcare · Biotechnology
15Tracked holders
0Δ holders
27.21MShares held
$664.97MReported value
+0New positions
−0Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +1.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | 0 | 35.14M | $539.55M | +6 | −6 |
| Q1 2026 | 80 | +4 | 31.30M | $434.70M | +12 | −8 |
| Q4 2025 | 75 | +1 | 36.09M | $498.13M | +1 | n/a |
| Q3 2025 | 15 | 0 | 27.21M | $664.97M | n/a | n/a |
| Q2 2025 | 12 | 0 | 25.28M | $583.88M | +1 | −1 |
| Q1 2025 | 9 | -2 | 8.77M | $236.76M | n/a | −2 |
| Q4 2024 | 11 | 0 | 8.88M | $475.25M | +1 | −1 |
| Q3 2024 | 10 | +1 | 4.53M | $205.89M | +1 | n/a |
| Q2 2024 | 9 | n/a | 5.15M | $215.67M | n/a | n/a |
Who holds it · Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 9.06M | +1.9% | $221.33M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 2 | BlackRock ✦ (passive) | 3.73M | +9.6% | $91.19M | 0.0% | ▲ Add | 2 | SEC ↗ ×15 |
| 3 | Adage Capital Partners ✦ | 2.77M | +9.9% | $67.82M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 4 | The Vanguard Group ✦ (passive) | 2.42M | +10.4% | $59.07M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (passive) | 1.89M | +36.3% | $46.23M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 1.71M | -20.2% | $41.80M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 1.27M | -29.4% | $30.93M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 8 | Geode Capital Management ✦ (passive) | 1.08M | +20.1% | $26.49M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 802.78K | -34.8% | $19.62M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 10 | Wellington Management ✦ | 701.60K | +42.5% | $17.15M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 11 | Goldman Sachs Group ✦ | 655.11K | n/a | $16.01M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Morgan Stanley ✦ | 495.63K | n/a | $12.11M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 13 | JPMorgan Chase ✦ | 418.37K | n/a | $10.22M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 14 | Two Sigma Investments ✦ | 103.48K | -0.9% | $2.53M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Millennium Management ✦ | 100.64K | -53.0% | $2.46M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 59.36M shares, $809.28M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2025 ·
Methodology ·
Get this via the API